Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2903276 | 1.00 | KDM4E (0.55) | KDM4EALOX15HSD17B10ALDH1A1LMNA | |
| SCHEMBL2177581 | 1.00 | KDM4E (0.55) | KDM4EALOX15HSD17B10ALDH1A1LMNA | |
| SCHEMBL668469 | 0.85 | USP2 (0.50) | KDM4EALOX15HSD17B10ALDH1A1LMNA | |
| SCHEMBL668470 | 0.85 | USP2 (0.50) | KDM4EALOX15HSD17B10ALDH1A1LMNA | |
| SCHEMBL29351668 | 0.85 | USP2 (0.50) | KDM4EALOX15HSD17B10ALDH1A1LMNA | |
| SCHEMBL16098806 | 0.85 | USP2 (0.50) | KDM4EALOX15HSD17B10ALDH1A1LMNA | |
| SCHEMBL1260983 | 0.83 | KDM4E (0.55) | KDM4EALOX15HSD17B10ALDH1A1LMNA | |
| SCHEMBL677540 | 0.83 | KDM4E (0.55) | KDM4EALOX15HSD17B10ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL29175072 | 0.83 | USP2 (0.49) | KDM4EALOX15HSD17B10ALDH1A1LMNA | |
| SCHEMBL5324787 | 0.83 | KDM4E (0.55) | KDM4EALOX15HSD17B10ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1039 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745244-A1 | ENGINEERING BIOLOGICAL CONTAINMENT SYSTEM AND METHOD | BGI Shenzhen (CN) | 2026-05-20 | — | — | EP | claimed |
| CN-119842625-A | Cell line for stably expressing orthogonal aminoacyl tRNA synthetase/tRNA pair | 浙江大学 | 2025-04-18 | — | — | CN | claimed |
| WO-2025010715-A1 | ENGINEERING BIOLOGICAL CONTAINMENT SYSTEM AND METHOD | 深圳华大生命科学研究院 | 2025-01-16 | — | — | WO | claimed |
| US-20240247034-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2024-07-25 | — | — | US | claimed |
| CN-117881779-A | Microorganism and use thereof | 英国研究与创新署 | 2024-04-12 | — | — | CN | claimed |
| US-20240117295-A1 | MICROORGANISMS AND USES THEREOF | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-04-11 | — | — | US | claimed |
| EP-4347799-A1 | MICROORGANISMS AND USES THEREOF | United Kingdom Research and Innovation (GB) | 2024-04-10 | — | — | EP | claimed |
| CN-117126873-A | Unnatural amino acid coding system and application thereof | 深圳华大生命科学研究院 | 2023-11-28 | — | — | CN | claimed |
| US-20230174596-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2023-06-08 | — | — | US | claimed |
| CN-115551878-A | Controlled modification of adeno-associated virus (AAV) for enhanced gene therapy | 波士顿学院董事会 | 2022-12-30 | — | — | CN | claimed |
| WO-2001093889-A2 | VIP-RELATED PEPTIDES FOR THE TREATMENT OF SKIN DISORDERS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2001-12-13 | — | — | WO | claimed |
| US-6211196-B1 | 8-BENZYLOXY-(TETRAHYDRO)QUINOLINE DERIVATIVES; LIVER CIRRHOSIS, ALZHEIMER*S DISEASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-04-03 | — | — | US | claimed |
| EP-1046627-A2 | Enantiopure reagents and process for the separation of enantiomers | SOLVAY (Société Anonyme) (BE) | 2000-10-25 | — | — | EP | claimed |
| EP-0808628-B1 | Use of non-peptide bradykinin antagonists for treating and preventing chronic fibrogenetic liver diseases, acute liver diseases and complications thereof | HOECHST AG (DE) | 2000-02-02 | — | — | EP | claimed |
| US-5952346-A | INHIBITS THE ACTIONS OF THE ALZHEIMER'S PROTEIN AMYLOID (BETA/A4) IN ISOLATED ENDOTHELIAL CELLS; QUINOLINE DERIVATIVES | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 1999-09-14 | — | — | US | claimed |
| EP-0835659-A1 | Use of non-peptidic bradykinin antagonists in the preparation of medicaments for the treatment and prevention of Alzheimer's disease | Hoechst Marion Roussel Deutschland GmbH (DE) | 1998-04-15 | — | — | EP | claimed |
| CN-1176102-A | Use of nonpeptide bradykinin antagonists for treatment and prevention of chronic fibrogenetic liver disorders acute liver disorders and complications associated therewith | HOECHST AG (DE) | 1998-03-18 | — | — | CN | claimed |
| EP-0808627-A2 | Use of non-peptide bradykinin antagonists for treating and preventing chronic fibrogenetic liver diseases, acute liver diseases and complications thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-26 | — | — | EP | claimed |
| EP-0808628-A2 | Use of non-peptide bradykinin antagonists for treating and preventing chronic fibrogenetic liver diseases, acute liver diseases and complications thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-26 | — | — | EP | claimed |
| US-4508645-A | CYCLIC OLIGOPEPTIDE CONTAINING PENICILLAMINE RESIDE | CESKOSLOVENSKA AKADEMIE VED (CS) | 1985-04-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240247034-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | LRP6, LDLR, KDR | KDM4E 3727/4885ALOX15 3884/4885HSD17B10 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.